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Abstract
Background: Ectromelia virus, a member of the Orthopox genus, is the causative agent of the
highly infectious mousepox disease. Previous studies have shown that different poxviruses induce
cell-cell fusion which is manifested by the formation of multinucleated-giant cells (polykaryocytes).
This phenomenon has been widely studied with vaccinia virus in conditions which require artificial
acidification of the medium.
Results: We show that Ectromelia virus induces cell-cell fusion under neutral pH conditions and
requires the presence of a sufficient amount of viral particles on the plasma membrane of infected
cells. This could be achieved by infection with a replicating virus and its propagation in infected cells
(fusion "from within") or by infection with a high amount of virus particles per cell (fusion "from
without"). Inhibition of virus maturation or inhibition of virus transport on microtubules towards
the plasma membrane resulted in a complete inhibition of syncytia formation. We show that in
contrast to vaccinia virus, Ectromelia virus induces cell-cell fusion irrespectively of its
hemagglutination properties and cell-surface expression of the orthologs of the fusion inhibitory
complex, A56 and K2. Additionally, cell-cell fusion was also detected in mice lungs following lethal
respiratory infection.
Conclusion: Ectromelia virus induces spontaneous cell-cell fusion in-vitro and in-vivo although
expressing an A56/K2 fusion inhibitory complex. This syncytia formation property cannot be
attributed to the 37 amino acid deletion in ECTV A56.
Background
Orthopox viruses are a family of large DNA viruses that
replicate in the cytoplasm of infected cells. There are two
major infective forms of the virus: a single-membrane
wrapped virion also known as mature virion (MV) and a
double-membrane wrapped virion, also known as envel-
oped virion (EV) [1]. An additional subdivision is used to
describe the different intracellular and extracellular forms
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of the virus. The intracellular progeny is subdivided to a
single-membrane wrapped virion also named as intracel-
lular-mature-virus (IMV) and to intracellular-enveloped-
virus (IEV) which is wrapped with two additional mem-
branes. The extracellular forms are divided to an extracel-
lular-cell-associated-virus and to the extracellular-
enveloped-virus (CEV and EEV respectively) [2]. Attach-
ment of EV particle to the cell results in the rupture of the
outer membrane by glucose-amino glycans (GAGs)
revealing single-membrane wrapped particle: the MV. At
this stage the mechanism, of entry is identical to that of
naked MV particle. During MV entry, the membrane fuses
either with the host-cell plasma membrane or with the
endosome membrane, releasing the viral core into the
cytoplasm [3]. Previous studies with the orthopox proto-
type vaccinia virus (VACV) or cowpox (CPXV) virus
showed that artificial decrease of the medium pH results
in the fusion of virus infected cells and syncytia forma-
tion. Syncytia formation under low-pH conditions is
largely separated into two major routes: One is induced by
large number of viral particles which are present in the
medium, attach the cell membrane and thus induce
fusion "from without". The other results from high
amount of intracellular viral particles, which induce
fusion "from within" [1].
Recently, a group of viral proteins was characterized as the
entry-fusion-complex (EFC). This complex comprises at
least 8 viral proteins: A16, A21, A28, G3, G9, H2, J5 and
L5 [4]. It was shown that deletion of certain members of
this complex result in inhibition of virus entry and of pH-
dependent cell-cell fusion. Thus, the current model for
poxvirus-induced cell-cell fusion relates syncytia forma-
tion to viral entry [1]. Early studies of the poxvirus hemag-
glutinin showed that hemagglutinating strains such as
vaccinia strain Western Reserve (VACV-WR), VACV-IHD-J
and CPXV do not induce syncytia at neutral pH condi-
tions, whereas at the same conditions, strains that do not
exhibit hemagglutinating properties (VACV-IHD-W, rab-
bitpox) induce cell-cell fusion [5]. Later it was demon-
strated that deletion of the hemagglutinin gene, namely
A56R, or inhibition of its protein product by inhibitory
antibodies result in the formation of syncytia by the
strains mentioned above under neutral pH conditions. In
addition, K2, a serine protease inhibitor (SPI-3) was also
shown to play a role in the fusion process [6]. Later on, K2
was shown to form a complex with A56R in infected cells
and addition of anti K2 antibodies to the medium of
CPXV infected cells also results in cell-cell fusion under
neutral pH conditions [7]. Thus, it is believed that the A56
and K2 form a complex which is inhibitory to syncytia for-
mation in poxviruses [1].
In this study we describe the formation of syncytia by
another member of the orthopox family, namely ectrome-
lia virus (ECTV) which is the causative agent of the mouse-
pox disease in mice [8]. We show that ECTV induces
syncytia formation under neutral pH conditions and in
the lungs of infected mice. This cell-cell fusion process
requires infection at high multiplicity of infection (MOI)
or following infection, replication and maturation of the
virus. We show that inhibition of virus maturation or
migration to the cell membrane inhibits cell-cell fusion,
whereas inhibition of virus egress or neutralization of
extracellular particles does not affect syncytia formation.
We further show that cell-cell fusion occurs despite cell
surface expression of the fusion inhibitory complex.
Results
ECTV induces syncytia in cultured cells
In order to study its cytopathic effect in cell culture, BS-C-
1 cells were infected with ECTV at MOI = 1. The cells were
incubated at pH 7.4 and 24 hours post infection (hpi)
cells were fixed, stained and cytopathic effect was evalu-
ated by immunofluorescence microscopy. The most
prominent cytopathic effect by ECTV was the formation of
syncytia which was manifested by polykaryocytosis (Fig.
1Aa and 1Ab). These giant multi-nucleated cells com-
prised few to tens of nuclei which were positioned in
many cases in a ring-shape form.
Importantly, formation of syncytia by ECTV occurred
under neutral pH conditions and acidification of the
medium did not enhance cell-cell fusion any further (data
not shown). These results are in contrast to syncytia for-
mation in VACV-WR infected cells which require acidifica-
tion of the medium to around pH5.5 in order to obtain
syncytia [1].
Whereas the actin cytoskeleton in un-infected control cells
remained well organized and exhibited actin stress-fibers
and marginal actin belt at the cell periphery (Fig 1A-a),
ECTV-infected syncytia, exhibited disrupted actin
cytoskeleton with no signs for actin cables and only poor
actin belt is surrounding the cell (Fig. 1A-b). Additionally,
infected cells contained actin-tails with ECTV at their tips
(Fig. 1A-e) which are typical to pox-virus egress [9]. Syn-
cytia formation was also observed, to a greater extent, in
human cervical cells (HeLa) where polykaryocytes con-
tained tens of nuclei and a completely disrupted actin
cytoskeleton (Fig. 1A-c and 1Ad).
Syncytia formation by ECTV is time- and dose-dependent
In order to follow the progression of syncytia formation,
BS-C-1 cell were infected at different MOI and cells were
fixed and stained at different time points post infection.
ECTV induced syncytia in a dose- and time-dependent
manner (Fig. 1B). Already 8 hours post infection cells
tended to aggregate towards a center before the induction
of cell-cell fusion and the formation of polykaryocytes (24Virology Journal 2009, 6:151 http://www.virologyj.com/content/6/1/151
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hours). In cells which were infected at MOI lower than 5,
polykaryocytes appeared in a ring-shape form and the
number of nuclei in multinucleated cells positively corre-
lated with the increase of moi. Increasing the MOI to 5 or
10 further emphasized this phenomenon where polykary-
cytosis was demonstrated throughout the entire culture.
Syncytia formation by ECTV requires sufficient amount of 
viral particles on the plasma membrane
Syncytia formation by poxviruses occurs by two distinct
mechanisms: "from within" by intracellular virus progeny
and "from without" when a large amount of virus is added
to the cells. To check weather ECTV particles can induce
syncytia formation also "from without" we infected HeLa
cells with either "live" virus in the presence of cyclohex-
imide (CHX, a potent inhibitor of protein synthesis) or
with UV-inactivated ECTV particles at high MOI (equiva-
lent to >100pfu/cell) at neutral pH. In both conditions,
already at 2 hpi the cultured cells were fused and syncytia
dominated the entire culture exhibiting giant polykaryo-
cytes consisting tens to hundreds nuclei (Fig. 2A). In con-
trast, when the infection load of UV-inactivated virus was
equal to MOI = 1 incubation with UV-inactivated virus
did not induce cell-cell fusion. Cells maintained their nor-
mal epithelial morphology and the actin cytoskeleton was
intact even at 24 hpi. No viral antigens were observed in
the cytoplasm (by immunofluorescence staining) and
viral particles which were apparent on the plasma mem-
brane at 8 hpi (Fig. 2B), were already absent at later time
points. Similar results were obtained in HeLa cells (not
shown). In order to further address the possible role of the
various infective forms of ECTV in cell-cell fusion, we
inhibited cellular processes which are crucial for poxvirus
morphogenesis.
A) Infection with ECTV induces cell-cell fusion Figure 1
A) Infection with ECTV induces cell-cell fusion. BS-C-1 and HeLa cells were infected with ECTV virus at MOI = 1. 24 hrs 
post infection cells were fixed and stained for DAPI (blue), actin (red) and ECTV (green). BS-C-1 control (a), BS-C-1 infected 
with ECTV (b), HeLa control (c), HeLa infected with ECTV (d). Bar = 100 μm. e) Actin tails (green) with ECTV particles (red) 
at their tips (designated with arrows). Bar = 1 μm. B) Induction of syncytia by ECTV virus is time and infection titer-depend-
ent. BS-C-1 cells were infected at different moi (0.25, 1, 5 and 10). At different time points cells were fixed and visualized by 
May-Grunwald and Gimsa staining. Bar = 100 μm.Virology Journal 2009, 6:151 http://www.virologyj.com/content/6/1/151
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To elaborate on the role of ECTV morphogenesis in syncy-
tia formation, we infected monolayers with ECTV at MOI
= 1 and incubated the cells in the presence of 0.5 μg/ml
Brefeldine-A (BFA) - a specific inhibitor of the trans-Golgi
network (TGN), nocodazole, or colchicine (two specific
inhibitors of microtubules dynamics) for 24 hours and
followed their effect on ECTV-induced syncytia forma-
tion. Deterioration of the TGN by BFA allowed for the rep-
lication of ECTV which was manifested by positive
staining in the cytoplasm (Fig. 3A) and the formation of
intracellular mature infectious virions (MV) at equal lev-
els to untreated cells (Fig. 4). However, release of infec-
tious viral particles from the cells to the medium was
inhibited by >80% (Fig 4) and syncytia formation was
completely inhibited (Fig. 3A). Similar results were
obtained by disruption of the microtubules network by
either nocodazole (Fig 3B) or colchicine (not shown).
There were no apparent changes in intracellular viral
staining and intracellular virus load was not altered by
either nocodazole or colchicine (Fig. 4). However, as with
BFA, in cells treated with these microtubules inhibitors,
extracellular virus levels dropped by 70%, staining for
microtubules was diffuse and no cell-cell fusion was
apparent.
In order to assure that inhibition of syncytia formation by
BFA, Colchicine and Nocodazole was a direct result of
morphogenesis inhibition, and not a consequence of cel-
lular damage, we infected cells with ECTV and treated
with the different inhibitors as described above. 16 hours
post infection, the inhibitors were washed-out and fresh
medium was added. Already 2-4 hours after withdrawal of
BFA or nocodazole cell-cell fusion resumed and polykary-
ocytes displayed 5 nuclei or more (Fig. 3A-bottom and
Fig. 3B-bottom respectively). Staining for α-tubulin dem-
onstrates that microtubules network reformed (in the case
of nocodazole- and BFA-treated cells) and that ECTV
staining was all over the cytoplasm, including cell bound-
ary. Washing out of colchicine did not resume microtu-
bules polymerization and syncytia formation was blocked
(not shown)
Poxvirus egress from the cell requires the formation of
actin tails which propels cell-associated extracellular virus
(CEV) away from its host cell prior to its release from the
cell by enzymatic activity of the cellular kinases Src and
Abl [9,10]. However, disruption of actin by cytochalasine-
D (Fig. 3C) or inhibition of actin tail formation by specific
src-kinase inhibitor PP1 (Fig. 3D) or SU6656 (not shown)
did not inhibit ECTV-dependent cell-cell fusion. Also
inhibition of virus release by the abl kinase-inhibitor STI-
571 [11] did not inhibit polykaryocytes formation (Fig.
3E). Moreover, addition of inhibitory antibody to ECTV
to the medium (Fig. 3F) at a concentration that inhibits
comet formation (Fig. 3F, inset) did not prevent cell-cell
fusion. In conclusion, the data so far points toward cell
membrane associated mature virions (MV) to be involved
in cell-cell fusion.
Cell-cell fusion occurs independently of A56/K2 inhibitory 
complex
Early studies established the correlation between the
orthopox-virus hemagglutinin (A56) and cell-cell fusion
under neutral-pH conditions. Generally, poxviruses that
have hemagglutination properties (i.e. VACV-WR, CPXV)
induce a cytopathic effect without the formation of syncy-
tia whereas viruses that induce cell-cell fusion (i.e. Rabbit-
pox, VACV-IHD-W) do not [12]. Inactivation of A56 by
antibodies that inhibit hemagglutination or silencing its
gene results in the formation of syncytia [5]. In addition,
K2, a serine protease inhibitor, was shown to cooperate
with A56 in its inhibitory effect on cell-cell fusion [6,13].
Syncytia formation by ECTV requires sufficient amount of  virus Figure 2
Syncytia formation by ECTV requires sufficient 
amount of virus. A) HeLa cells were infected with either 
UV-inactivated virus (a) or live virus in the presence of 100 
μg/ml cycloheximide (b) at MOI = 100. The cells were fixed 
after 2 hours and stained with May-Grunwald and Gimsa 
staining. B) BS-C-1 cells were infected with live or U.V-irra-
diated virus at moi = 1. After 8 or 24 hours the cells were 
fixed and stained for ECTV (green) and actin (red).Virology Journal 2009, 6:151 http://www.virologyj.com/content/6/1/151
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Effect of different inhibitors on cell-cell fusion Figure 3
Effect of different inhibitors on cell-cell fusion. HeLa cells were infected with ECTV at moi = 1 and incubated for 16 
hours with different inhibitors. A) Cells incubated with 0.5 μg/ml BFA. B) Cells incubated with 5 μM nocodazole. Bottom 
images of each panel represent cells 4 hours after withdrawal of the inhibitor. C, D, E and F: Cells incubated with 0.5 μM 
cytochalasine-D, 10 μM PP1, 10 μM STI-571 and antiserum to ECTV, respectively. Inset in F demonstrates ECTV comet inhibi-
tion assay with anti-ECTV serum.Virology Journal 2009, 6:151 http://www.virologyj.com/content/6/1/151
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We therefore wanted to verify whether the orthologs of
A56 and K2 are expressed by ECTV and to evaluate the
hemagglutination properties of the ECTV A56 ortholog
(EVM151). Western blot analysis showed that both
orthologs of K2 and A56 were expressed in ECTV-infected
cells and that both proteins have faster mobility in SDS-
PAGE in comparison to their VACV-WR orthologs. (Fig.
5A). We further substantiated previous results [14] show-
ing that the Moscow strain of ECTV, which is utilized
throughout this study presents hemmaglutination ability
(endpoint titer of 1:4) in comparison to the hemaggluti-
nin-negative rabbitpox strain (RPXV) (endpoint 0) and to
the hemagglutinating strain VACV-WR (endpoint 1:16).
Multiple alignment of the amino-acid sequence of A56
orthologs from different poxviruses (Fig. 5B) shows that
ECTV A56 ortholog is missing a 37 amino acid stretch
which is present in VACV-WR and in part in Cowpox - two
hemagglutinating strains. To check whether this deletion
prevents interaction of A56 with K2 and by that formation
of a functional inhibitory complex, we infected HeLa cells
with ECTV, VACV-WR, CPXV or RPXV and verified the
ability of K2 to associate with A56 by co-immunoprecipi-
tation. Figures 5C demonstrates an interaction between
A56 and K2 of ECTV, regardless of the deleted amino acid
stretch, as in the case of VACV-WR and Cowpox. As K2
bares no transmembrane domain, nor a membrane
anchoring motif, its presence on the plasma membrane of
infected cells is mediated through its interaction with A56
[7]. This interaction forms the inhibitory fusion complex.
In order to check whether a fusion inhibitory complex of
the ECTV orthologs of A56-K2 is localized on the surface
of infected cells, we infected cells with either ECTV, Cow-
pox or RPXV and 24 later immunolabelled the cells sur-
face for either K2 or A56 by a technique that was described
previously [7]. Indeed, both A56 and K2 were localized on
the plasma membrane of both Cowpox and ECTV
infected cells (Fig. 6A and 6B respectively). These markers
were not detected in our control-RPXV-infected cells nei-
ther by immunostaining (Fig. 6) nor by immunoblotting
(Fig. 5C) since K2 is rapidly secreted in the absence of its
membrane anchoring counterpart, namely A56 [4]. These
results demonstrate that ECTV induces syncytia under
neutral pH conditions despite the presence of A56/K2
complex on the cell membrane.
Having demonstrated that the A56 ortholog of ECTV dif-
fers in sequence and length from VACV-A56, we checked
whether ectopic expression of a functional A56 with a
known inhibitory effect on cell-cell fusion would inhibit
syncytia formation by ECTV. For this purpose we used
VACV-WR as a vector for expression of A56 which was pre-
viously shown to inhibit cell-cell fusion under neutral-pH
conditions [15]. We co-infected cells with both ECTV and
VACV-WR and followed their cytopathic effect. At 24 hpi
VACV-WR-infected cells exhibited a typical small rounded
morphology (Fig.7A-b) but did not exhibit any polykary-
ocytes, whereas ECTV-infected cells exhibited cell-cell
fusion as described above (Fig.7A-a). Interestingly, cells
that were co-infected with both ECTV and VACV-WR at
MOI ratio of 1:1 or even 1(ECTV):10(WR) still formed
syncytia (Fig.7A-cc and 7Ad respectively). These polykary-
ocytes were comparable in size and nuclei number to cells
that were infected with ECTV alone.
Effect of different inhibitors on intra- and extracellular progeny of ECTV Figure 4
Effect of different inhibitors on intra- and extracellular progeny of ECTV. HeLa cells were infected with ECTV at 
MOI = 5 and incubated with different inhibitors (0.5 μg/ml BFA, 5 μM nocodazole, 5 μM colchicine or 100 ng/ml cyclohex-
imide) for 24 hours. Titers of intracellular (A) and extracellular (B) virus were determined by plaque assay. Error bar = SD.Virology Journal 2009, 6:151 http://www.virologyj.com/content/6/1/151
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These results were also confirmed by ectopic expression of
VACV-WR A56. In order to restrict expression of VACV-
WR A56 to ECTV infected cells, and to distinguish
between the ECTV and VACV-WR A56 we fused the WR-
A56R open reading frame to the Green Fluorescent Pro-
tein (GFP) under the regulation of the early/late p7.5 pro-
moter. We infected HeLa cells with the ECTV at MOI = 1
followed by transfection with A56R-GFP. Expression of
VACV-WR A56-GFP was detected only in ECTV infected
cells. Nevertheless, this expression did not inhibit cell-cell
fusion induced by ECTV infection (Fig. 7B).
ECTV infection induces cell-cell fusion in-vivo
ECTV is a highly virulent mouse pathogen. Previous stud-
ies have shown that other poxviruses such as Monkeypox,
Camelpox and Raccoonpox, which are virulent to their
natural host, can induce cell-cell fusion in-vitro and in
some cases also in-vivo [16-18]. Therefore, we wanted to
check whether ECTV induces cell-cell fusion in-vivo. For
this purpose we infected BALB/c mice with a lethal dose
(10LD50) of ECTV by the intranasal route and examined
their lungs at different time points post infection by his-
tology. At early stages of infection (up to day 6 post infec-
tion) the lungs of ECTV infected mice kept their overall
alveolar and bronchi architecture (Fig. 8A and 8B). Syncy-
tia consisting 5 nuclei or more were also exhibited sporad-
ically (Fig. 8A, syncytia containing and normal naive
regions are designated with black arrows). At later stages,
the lung epithelium exhibited progressive damage that
spread to the surrounding alveoli and correlated with the
presence of viral antigens as appears by immunohisto-
chemistry (Fig. 8B).
Discussion
Virus induced cell-cell fusion (syncytia) is a well-charac-
terized phenomenon in many viruses [19]. In poxviruses,
syncytia formation was deeply characterized by the WR
strain of vaccinia virus. Induction of cell-cell fusion by
VACV-WR can be achieved either directly by infection
with high amount of virions per cell or several hours post
infection at lower MOI, followed by virus replication and
sorting to the cell membrane [1]. Under these conditions,
when sufficient amount of virus is presented on the
plasma membrane, brief acidification of the medium
Expression and complex formation of A56 and K2 by ECTV Figure 5
Expression and complex formation of A56 and K2 by ECTV. A) Expression of A56 and K2 by VACV-WR and ECTV. 
α-VACV-WR antibody was used as control to viral-proteins expression. B) Amino-acids sequence alignment of A56 of VACV-
WR, ECTV, CPXV and RPXV. C) Co-immunoprecipitation of K2 and A56. Cells were infected with ECTV, VACV-WR, CPXV, 
RPXV or uninfected. K2 was immunoprecipitated (IP) and its interaction with A56 was evaluated by immunoblot (left side of 
the panel). Expression of K2, A56 as well as A33 (control for infection) and α-tubulin (cellular marker) are presented on the 
right side of the panel.Virology Journal 2009, 6:151 http://www.virologyj.com/content/6/1/151
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results in a fast syncytia formation. Reducing the pH is
believed to resemble fusion of the viral membrane with
the membrane of the acidified endosomes during virus
entry or direct fusion of the viral membrane with the cell
membrane [1,20]
In this study we show that ECTV induces syncytia forma-
tion in dose- and time-dependent manner. Similar to
VACV, ECTV induces cell-cell fusion when sufficient
amount of virus is presented on the plasma membrane;
either by infection at high MOI or by allowing enough
time for virus replication and sorting to the plasma mem-
brane. However, unlike VACV which requires medium
acidification for the fusion to occur, ECTV induces syncy-
tia formation under physiological pH conditions. Infec-
tious forms of Orthopox viruses comprise of intracellular
mature viruses (MV), extracellular wrapped viruses (EV)
and the intracellular enveloped viruses (IEV). These forms
differ in their cellular localization and contain either sin-
gle, double or three layers of membranes respectively [2].
To have an indication as to which of the different viral
forms plays a role in cell-cell fusion, we utilized specific
chemical inhibitors to several cellular processes aiming to
block poxvirus maturation at different stages. Brefeldin-A
(BFA) is a specific inhibitor which disrupts the trans-Golgi
network (TGN) and hence inhibits wrapping of the virus
with the two additional membranes [21] and thereby pre-
vents the formation of IEV. The transport of IEV towards
the cell membrane is facilitated by microtubules dynam-
ics [22,23]. Therefore, perturbation of microtubules
dynamics prevents microtubules-dependent, intracellular
transport of poxviruses. Using these inhibitors, we
showed that when virus egress is inhibited, cell-cell fusion
is prevented. It is worth mentioning that these inhibitors
did not affect production of infectious intracellular
mature virions (Fig. 4). When later stages of virus release
were inhibited by inhibitors, such as PP1 which inhibits
actin tail formation or STI-571 which inhibits virus release
from the plasma membrane, or by inhibiting extracellular
virions using neutralizing antibodies (Fig. 3), cell-cell
fusion still occurred. These results point towards the cell-
membrane- associated-mature virion (MV) as the viral
particle which probably mediates cell-cell fusion.
Previous studies have identified a fusion entry complex
embedded within the membrane of the mature virion
(MV) [1] and an inhibitory fusion complex which com-
prises of two viral proteins: the poxvirus hemagglutinin-
A56 and the serine protease inhibitor 3 (SPI-3) K2 which
is presented on the plasma membrane of poxvirus
infected cells [13,24,25]. Classical studies with poxviruses
have established a counter relationship between hemag-
glutination and fusion properties of the poxviruses.
Hence, poxviruses which hemagglutinate red blood cells,
do not induce spontaneous cell-cell fusion, and vice-versa
[5]. Deletion of either genes or inhibition of their protein
products by inhibitory antibodies results in syncytia for-
mation [5,15,26]. Recent studies clearly demonstrated
that the presence of A56 and K2, whether expressed by the
virus, or expressed by the cellular machinery, inhibit cell-
cell fusion [25].
In this article we show that ECTV, which is a hemaggluti-
nating strain, expresses the orthologs of the two proteins,
Localization of A56 and K2 on the plasma membrane of  ECTV infected cells Figure 6
Localization of A56 and K2 on the plasma membrane 
of ECTV infected cells. HeLa Cells were infected with 
ECTV, CPXV or RPXV at MOI = 1. 24 hpi membrane associ-
ated A56 (A) or K2 (B) were visualized by "live" immunola-
beling followed by fixation and indirect immunofluorescence 
staining. Actin cytoskeleton and nuclei were labeled as cellu-
lar counter-staining.Virology Journal 2009, 6:151 http://www.virologyj.com/content/6/1/151
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EVM151 (ortholog of VACV-A56) and EVM23 (ortholog
of K2) (Fig. 5A). Thus, cell-cell fusion is induced by ECTV
regardless of the expression of these two proteins. Accord-
ing to SDS-PAGE analysis, the two proteins have faster
mobility than their orthologues from VACV-WR. This
could be explained by the 37 amino acids deletion in
EVM151 (Fig. 5B) and by differences in glycosylation pat-
tern of EVM23 as predicted by its amino acids sequence
(data not shown).
The fact that EVM151 bares a 37 amino acids deletion
raised the possibility that this deletion might be responsi-
ble for the fusogenic property of the virus. Previous stud-
ies have identified different mutants of VACV which
induce spontaneous cell-cell fusion while retaining
hemagglutination properties [27]. However, none of
these mutations resides in the 37 amino acids stretch
which is deleted in ECTV hemagglutinin. We wanted to
exclude the possibility that this deletion prevents interac-
tion of A56 with K2 and thus fusion inhibitory complex
cannot form. Indeed, co-immunoprecipitation assay
showed that EVM23 interacts with EVM151 in a similar
manner to this interaction in VACV-WR or cowpox virus.
Additionally, we showed that K2 and A56 are localized
properly on the plasma membrane of ECTV infected cells
(Fig. 6).
We also showed that expression of A56 from a hemagglu-
tinating strain (VACV-WR) in ECTV infected cells could
not inhibit cell-cell fusion (Fig. 7B). This was further sub-
stantiated by co-infection of ECTV and VACV-WR. In this
experiment cells infected by both viruses expressed a func-
tional A56/K2 inhibitory complex. However, the appear-
ance of syncytia indicates that ECTV-dependent cell-cell
fusion is not a consequence of an un-functional inhibi-
tory complex.
Recent studies have established a model for poxvirus
entry. In this model, the poxvirus entry fusion complex
(EFC) comprises at least 8 proteins: H2, G3, A28, A21, L5,
J5, G9 and A16. Each of these proteins is crucial for the
formation of an active EFC. Within the EFC, G9 and A16
form a complex which interacts with the fusion inhibitory
- A56/K2 - complex which is presented on the plasma
membrane of poxvirus-infected cells[6,13]. This interac-
tion prevents the fusion of the intracellular mature virus
membrane with the plasma membrane of an already
infected cell [13]. When either A56 or K2 are inactive, the
inhibitory interaction between the EFC and the A56/K2
complex is abrogated and hence cell-cell fusion is appar-
ent (i.e. RPXV). In this study we demonstrated that ECTV
expresses and presents the A56/K2 complex on the plasma
membrane of infected cells yet cell-cell fusion still occurs,
ECTV induces syncytia regardless of A56 or K2 expression Figure 7
ECTV induces syncytia regardless of A56 or K2 expression. A) Co-infection of HeLa cells with ECTV and VACV-WR. 
Cells were infected with either ECTV (a) VACV-WR (b), or co-infected with both viruses in a ratio of 1:1 or 1:10 (c and d 
respectively). 24 hours post infection cells were fixed and stained. B) Co-transfection-infection of VACV-WR A56 and ECTV 
in HeLa cells. Cells were infected with ECTV at MOI = 1 and transfected with pBS-A56R-GFP as described in Materials and 
Moethods. 24 hpi cells were fixed and stained for GFP (green), ECTV (red) and nuclei (DAPI).Virology Journal 2009, 6:151 http://www.virologyj.com/content/6/1/151
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suggesting that in ECTV the EFC is no longer inhibited by
the A56/K2 complex. Since A56 and K2 do not seem to be
the cause for this lack of interaction, the reason might
reside in the structure/function of either G9 or A16. The
amino acids compositions of these two proteins were
compared to their orthologs in VACV but only minor
changes in their sequence were found. These minor
changes might affect the interaction of the EFC with the
A56/K2 complex even though we cannot exclude the role
of other possible members of the EFC in cell-cell fusion.
Induction of cell-cell fusion under neutral pH conditions
have been documented with other virulent poxviruses
such as Monkeypox [17], Raccoonpox and Volepox [28]
We showed here that syncytia formation in ECTV infected
cells can be detected in lung epithelium following lethal
respiratory infection of mice, the natural host of ECTV.
Whether a similar mechanism of cell-cell fusion exists in
other natural Orthopox viruses is yet to be investigated.
Methods
Cells and viruses
BS-C-1 (ATCC, CCL-26) and HeLa (ATCC, CCL-2) cells
were routinely maintained in Dulbecco's Modified Eagle
Medium (DMEM) supplemented with 10% fetal calf
serum, 2 mM glutamine, 0.1 mg/ml streptomycin, 100
units/ml penicillin, 1.25 units/ml nystatin and non-essen-
tial amino acids (Biological Industries, Israel). VACV-WR
(ATCC VR-119), VACV-IHD-J, RPXV (strain Utrecht,
ATCC VR-157), CPXV (strain Brighton, ATCC VR-302)
and ECTV (strain Moscow, ATCC VR-1374), were grown
in HeLa cells and purified as described previously [29].
Viral titers were determined by plaque assay on BS-C-1
monolayers.
For inactivation of ECTV, purified virus (108pfu/ml) in
PBS was UV-irradiated with a PHILIPS G30T8 sterilamp in
open 60 mm dish for 15 minutes. The virus suspension
was gently agitated during the treatment and virus inacti-
vation was validated by plaque assay.
Hemagglutination assay
Hemagglutination properties of VACV-WR, RPXV and
ECTV were preformed on 108pfu/ml virus stocks and eval-
uated as described elsewhere [30].
Antibodies and reagents
For production of Rabbit anti- IMV and anti EEV antisera
- Vaccinia IHD-J was propagated in a suspension of HeLa
S3 cells grown in DMEM supplemented with 2% FCS.
Cells were infected at an MOI of 0.1 and when CPE was
evident the medium was clarified from cell debris by cen-
trifugation (200 g). Intracellular progeny was purified
from the cells by three freeze-thaw rounds followed by
sonication (3 times 4,000 Joules 1 minute each). The
resulting suspension was separated from cell debris by
low speed centrifugation (200 g, 5 minutes at 4°C) loaded
on a 36% (W/V) sucrose cushion and concentrated by
ultracentrifugation (13,500 RPM, SW28 Beckman rotor)
at 4°C for 80 minutes. The resulting pellet was suspended
in PBS and purified through a sucrose gradient (25-50%
W/V) by centrifugation at 40000 RPM with Ti 45 rotor
(Sorval/Beckman) at 4°C for 80 minutes.
ECTV infection induces cell-cell fusion and cellular damage in  mouse lung epithelium Figure 8
ECTV infection induces cell-cell fusion and cellular 
damage in mouse lung epithelium. BALB/c mice were 
infected with either mock or 10LD50 of ECTV by the intrana-
sal route. At days 4-6 post infection, the animals were sacri-
ficed and lung samples were analyzed by hematoxylin-eosine 
as well as immunohistochemical staining. A) ECTV-induced 
syncytia in bronchi of infected mice lung. Regions of fused 
cells are designated with black arrows. B) Damage progres-
sion in lung epithelium following ECTV infection after 4 or 8 
days post infection (upper and lower images, respectively). 
Sequential Slices were stained by hematoxylin and Eosine 
(left) or labeled by immunohistochemical staining using Rab-
bit anti ECTV serum (right).Virology Journal 2009, 6:151 http://www.virologyj.com/content/6/1/151
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Extracellular virus particles were purified from the culture
media by ultracentrifugation as described above. The pel-
let was re-suspended in PBS and purified through a
sucrose gradient (25-50% W/V) by ultracentrifugation.
The bands of IMV and EEV particles were dialyzed against
PBS, titrated on BS-C-1 monolayers and inactivated by
betapropiolactone (βPL) (Serva, Germany).
For preparation of the anti IMV and anti EEV antisera, rab-
bits (New Zealand white, female) were vaccinated subcu-
taneously with equivalent dose of 1 × 106pfu of the
desired antigen (βPL inactivated IMV or EEV) formulated
in complete Freud adjuvant (Sigma) followed by 3 addi-
tional injections every 21 days with the same antigen for-
mulated in incomplete Freud adjuvant.
For production of anti Ectromelia hyper immune sera,
rabbits (New Zealand white, female) were vaccinated sub-
cutaneously with 1 × 107pfu, 4 times every 21 days with
viable, sucrose purified virus in PBS. Blood was collected
14 days after the final boost and separated in collection
tubes (BD) by centrifugation.
Anti A33 antiserum was produced by vaccination of rab-
bits (New Zealand white, female) with bacterial
expressed, purified His-tagged A33 formulated with com-
plete Freud adjuvant followed by 2 additional injections
every 21 days with the same antigen formulated in incom-
plete Freud adjuvant.
Rabbit anti K2 and Rabbit anti A56 were a kind gift from
Dr. Bernard Moss (NIH, USA) [4]. Mouse anti HA (clone
1H831) was kindly provided by Dr. Hisatoshi Shida
(Hokkaido University, Japan), Mouse anti SPI-3 (clone
4A11-4A3) was kindly provided by Dr. Richard Moyer
(UFL, USA).
Mouse anti α-tubulin was purchased from Sigma immun-
ochemical (MO, USA). As secondary antibody reagents,
we used Alexa-555-conjugated goat anti mouse or anti
rabbit antibodies and Alexa488-conjugated goat anti
mouse or goat anti rabbit antibodies (Invitrogen, USA).
For Western-blot we used HRP-conjugated goat anti rabbit
antibody (Roche). Actin filaments were labeled with
TRITC or FITC-labeled Phalloidin and nuclei were visual-
ized by 4',6-Diamidino-2-phenylindole (DAPI), all from
Sigma Immunochemicals. The following inhibitors:
Brefeldine-A (BFA), cycloheximide, Arabinoside-cytosine
(Ara-C), PP1, nocodazole, colchicine and cytochalasin-D
were also from Sigma Inmmunochemicals.
Infection and comet assay
For infection with the different poxviruses, manslayers of
cells in 6-well or 12-well dish were rinsed twice with PBS
before virus, at the desired MOI, was added to the
medium in a volume of 0.2 ml. The cells were incubated
at 37°C or 4°C for one hour, rinsed with PBS and further
incubated in Eagle's minimal essential medium supple-
mented with 2% FCS at 37°C.
Comet assay was preformed as described elsewhere [31].
Immunofluorescence staining, histology, immunohistochemistry and 
image acquisition
For Immunofluorescence labeling cells were plated on 13
mm round glass coverslips (Marienfeld, Germay). Follow-
ing the different infections and treatments cells were fixed
in 3% paraformaldehyde (PFA) in PBS for 20 minutes and
permeabilized with 0.5% Triton X-100 for 2 minutes. The
fixed cells were rinsed with PBS, blocked with 2% Bovine
Serum Albumin (Sigma) and the coverslips were incu-
bated for 45 minutes with the primary antibodies. After
washing with PBS, cells were incubated with the appropri-
ate fluorescent secondary antibodies for 30 minutes. For
DNA visualization we incubated the coverslips with 5 μg/
ml DAPI. After additional washes with PBS, the coverslips
were mounted with Elvanol (Mowiol, 4-88, Hoechst, Ger-
many) on glass slides.
Histology was preformed on thin paraffin-embedded sec-
tions. Serial sections were stained with either hematoxylin
and eosin or stained with anti-VACV hyper-immune
serum using EnVision kit (Dakocytomation).
Microscopy and Fluorescence microscopy were carried out
using the Nikon TE2000 fluorescent microscope. The
images were acquired by a Nikon DXM-1200F camera and
processed with Adobe Photoshop software.
One step growth
Cells were infected with ECTV at MOI = 5 for 1 hour at
37°C as described above. 2 hours post infection different
chemical inhibitors were added at the desired concentra-
tions and the cells were further incubated at 37°C for 24
hours. At this time point the medium was gently collected
from the dishes and cell debris were separated by centrif-
ugation. Cells were scrapped, underwent freeze-thaw steps
for 3 times and sonicated 3 times for 30 seconds. Intracel-
lular and extracellular viral titers were determined by
plaque assay on BS-C-1 monolayers.
Plasmids and co-transfection-infection
Construction of VACV-WR A56R fused to GFP under the
regulation of p7.5 early/late promoter was carried out by
the polymerase chain reaction (PCR).
For the p7.5 promoter we used the VACV genome as a
template and the primers NE5: AACTGCAGTTTTTATAG-
TAAGTTTTT (PstI site in bold) and NE16: TCCCCCCG-
GGCTACTTCCTTACCGTGCA (XmaI site in bold). For theVirology Journal 2009, 6:151 http://www.virologyj.com/content/6/1/151
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A56R gene of VACV-WR we used the primers NE17:
TCCCCCCGGGATGACACGATTACCAATA (XmaI site in
bold) and and NE18: CGCGGATCCGACTTTGTTCTCT-
GTTTT (BamHI in bold).
The GFP gene was amplified using the primers NE20:
CGCGGATCCATGGTGAGCAAGGGCGAG (BamHI site
in bold) and NE21: TTTTCCTTTTGCGGCCGCTTACTTG-
TACAGCTCGTC (NotI site in bold).
The resulted DNA fragments were digested by restriction
enzymes acroding to their restriction sites and ligated with
T4  ligase. The resulting p7.5-A56R-GFP fragment was
amplified by PCR using primers NE5 and NE21 and the
PCR product was inserted into PstI and NotI sites of
pBluescript vector (Stratagene) to give pBS-A56R-GFP.
For co- transfection-infection experiments, HeLa cells
were grown on 13 mm coverslips in 24 well dish until
reaching 80-90% confluence. Cells were infected with
ECTV at MOI = 1 for 1 hr at 37°C, washed twice with
DMEM and transfected with 2 μg pBS-A56R-GFP by Lipo-
fectamine 2000 (invitrogen). 24 hours later cells were
fixed and stained for the desired proteins.
Immunoblot analysis
HeLa cells were infected with VACV-WR, CPXV, RPXV or
ECTV at MOI = 1. After 1 hour, the cells were washed three
times with PBS and further incubated at 37°C. 24 hpi the
dishes were washed twice with PBS and the cells were
scrapped with rubber policeman. Immunoprecipitation,
SDS-page and Western-blot analysis were preformed as
described previously [32].
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
NE carried out the experiments and data analysis, cloned
the pBS-A56R-GFP plasmid for transfections and drafted
the manuscript. NP and SL participated in experiments
design, data analysis and manuscript preparation. GMR
did the immunoprecipitation and immunoblot assays. BP
participated in in-vivo experiments and prepared histol-
ogy samples. PS and PF participated in cell-culture infec-
tions. TI and SM participated in in-vivo experiments.
Acknowledgements
We thank Yossi Shlomovich and Dr. Udy Olshevsky for their assistance 
with production of rabbit sera. Dr. Bernard Moss (NIH, USA) for the Rab-
bit anti K2 and Rabbit anti A56 antibodies, Dr. Richard Moyer (UFL, USA) 
for the Mouse anti SPI-3 and Dr. Hisatoshi Shida (Hokkaido University, 
Japan) for the mouse anti HA antibody.
References
1. Moss B: Poxvirus entry and membrane fusion.  Virology 2006,
344:48-54.
2. Smith GL, Vanderplasschen A, Law M: The formation and func-
tion of extracellular enveloped vaccinia virus.  J Gen Virol 2002,
83:2915-2931.
3. Carter GC, Law M, Hollinshead M, Smith GL: Entry of the vaccinia
virus intracellular mature virion and its interactions with gly-
cosaminoglycans.  J Gen Virol 2005, 86:1279-1290.
4. Wagenaar TR, Moss B: Association of vaccinia virus fusion reg-
ulatory proteins with the multicomponent entry/fusion com-
plex.  J Virol 2007, 81:6286-6293.
5. Ichihashi Y, Dales S: Biogenesis of poxviruses: interrelationship
between hemagglutinin production and polykaryocytosis.
Virology 1971, 46:533-543.
6. Turner PC, Moyer RW: Orthopoxvirus fusion inhibitor glyco-
protein SPI-3 (open reading frame K2L) contains motifs
characteristic of serine proteinase inhibitors that are not
required for control of cell fusion.  J Virol 1995, 69:5978-5987.
7. Turner PC, Moyer RW: The cowpox virus fusion regulator pro-
teins SPI-3 and hemagglutinin interact in infected and unin-
fected cells.  Virology 2006, 347:88-99.
8. Fenner F: The pathogenesis of the acute exanthems; an inter-
pretation based on experimental investigations with mouse-
pox; infectious ectromelia of mice.  Lancet 1948, 2:915-920.
9. Smith GL, Law M: The exit of vaccinia virus from infected cells.
Virus Res 2004, 106:189-197.
10. Newsome TP, Weisswange I, Frischknecht F, Way M: Abl collabo-
rates with Src family kinases to stimulate actin-based motil-
ity of vaccinia virus.  Cell Microbiol 2006, 8:233-241.
11. Reeves PM, Bommarius B, Lebeis S, McNulty S, Christensen J, Swimm
A, Chahroudi A, Chavan R, Feinberg MB, Veach D, et al.: Disabling
poxvirus pathogenesis by inhibition of Abl-family tyrosine
kinases.  Nat Med 2005, 11:731-739.
12. Shida H, Dales S: Biogenesis of vaccinia: molecular basis for the
hemagglutination-negative phenotype of the IHD-W strain.
Virology 1982, 117:219-237.
13. Wagenaar TR, Ojeda S, Moss B: Vaccinia virus A56/K2 fusion reg-
ulatory protein interacts with the A16 and G9 subunits of the
entry fusion complex.  J Virol 2008, 82:5153-5160.
14. Mills T, Pratt BC: Differentiation of ectromelia virus haemag-
glutinin from haemagglutinins of other poxviruses.  Arch Virol
1980, 63:153-157.
15. Turner PC, Moyer RW: An orthopoxvirus serpinlike gene con-
trols the ability of infected cells to fuse.  J Virol 1992,
66:2076-2085.
16. Otterbein CK, Meyer H, Renner-Muller IC, Munz E: In vivo and in
vitro characterization of two camelpoxvirus isolates with
decreased virulence.  Rev Elev Med Vet Pays Trop 1996, 49:114-120.
17. Reed KD, Melski JW, Graham MB, Regnery RL, Sotir MJ, Wegner MV,
Kazmierczak JJ, Stratman EJ, Li Y, Fairley JA, et al.: The detection of
monkeypox in humans in the Western Hemisphere.  N Engl J
Med 2004, 350:342-350.
18. Thomas EK, Palmer EL, Obijeski JF, Nakano JH: Further character-
ization of Raccoonpox virus.  Arch Virol 1975, 49:217-227.
19. Earp LJ, Delos SE, Park HE, White JM: The many mechanisms of
viral membrane fusion proteins.  Curr Top Microbiol Immunol
2005, 285:25-66.
20. Townsley AC, Weisberg AS, Wagenaar TR, Moss B: Vaccinia virus
entry into cells via a low-pH-dependent endosomal pathway.
J Virol 2006, 80:8899-8908.
21. Ulaeto D, Grosenbach D, Hruby DE: Brefeldin A inhibits vaccinia
virus envelopment but does not prevent normal processing
and localization of the putative envelopment receptor P37.
J Gen Virol 1995, 76(Pt 1):103-111.
22. Hollinshead M, Rodger G, Van Eijl H, Law M, Hollinshead R, Vaux DJ,
Smith GL: Vaccinia virus utilizes microtubules for movement
to the cell surface.  J Cell Biol 2001, 154:389-402.
23. Ward BM, Moss B: Vaccinia virus intracellular movement is
associated with microtubules and independent of actin tails.
J Virol 2001, 75:11651-11663.
24. Turner PC, Moyer RW: The vaccinia virus fusion inhibitor pro-
teins SPI-3 (K2) and HA (A56) expressed by infected cells
reduce the entry of superinfecting virus.  Virology 2008,
380:226-233.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Virology Journal 2009, 6:151 http://www.virologyj.com/content/6/1/151
Page 13 of 13
(page number not for citation purposes)
25. Wagenaar TR, Moss B: Expression of the A56 and K2 proteins
is sufficient to inhibit vaccinia virus entry and cell fusion.  J
Virol 2009, 83:1546-1554.
26. Stern W, Dales S: Biogenesis of vaccinia: isolation and charac-
terization of a surface component that elicits antibody sup-
pressing infectivity and cell-cell fusion.  Virology 1976,
75:232-241.
27. Seki M, Oie M, Ichihashi Y, Shida H: Hemadsorption and fusion
inhibition activities of hemagglutinin analyzed by vaccinia
virus mutants.  Virology 1990, 175:372-384.
28. Knight JC, Goldsmith CS, Tamin A, Regnery RL, Regnery DC,
Esposito JJ: Further analyses of the orthopoxviruses volepox
virus and raccoon poxvirus.  Virology 1992, 190:423-433.
29. Melamed S, Paran N, Katz L, Ben-Nathan D, Israely T, Schneider P,
Levin R, Lustig S: Tail scarification with Vaccinia virus Lister as
a model for evaluation of smallpox vaccine potency in mice.
Vaccine 2007, 25:7743-7753.
30. Hierhozler JC, Killington RA: Virus isolation and quantitaion Academic
Press; 1996. 
31. Fogg C, Lustig S, Whitbeck JC, Eisenberg RJ, Cohen GH, Moss B: Pro-
tective immunity to vaccinia virus induced by vaccination
with multiple recombinant outer membrane proteins of
intracellular and extracellular virions.  J Virol 2004,
78:10230-10237.
32. Erez N, Zamir E, Gour BJ, Blaschuk OW, Geiger B: Induction of
apoptosis in cultured endothelial cells by a cadherin antago-
nist peptide: involvement of fibroblast growth factor recep-
tor-mediated signalling.  Exp Cell Res 2004, 294:366-378.